Abstract:Primary human hepatocyte (PHH) transplantation is a promising alternative to liver transplantation, whereby liver function could be restored by partial repopulation of the diseased organ with healthy cells. However, currently PHH engraftment efficiency is low and benefits are not maintained long-term. Here we refine two male mouse models of human chronic and acute liver diseases to recapitulate compromised hepatocyte proliferation observed in nearly all human liver diseases by overexpression of p21 in hepatocytes. In these clinically relevant contexts, we demonstrate that transient, yet robust expression of human hepatocyte growth factor and epidermal growth factor in the liver via nucleoside-modified mRNA in lipid nanoparticles, whose safety was validated with mRNA-based COVID-19 vaccines, drastically improves PHH engraftment, reduces disease burden, and improves overall liver function. This strategy may overcome the critical barriers to clinical translation of cell therapies with primary or stem cell-derived hepatocytes for the treatment of liver diseases.

What problem does this paper attempt to address?

The main issue this paper attempts to address is improving the cell engraftment efficiency of primary human hepatocytes (PHH) in the treatment of liver diseases. Specifically, the paper explores how to enhance PHH engraftment in mouse models, reduce disease burden, and restore liver function by expressing growth factors delivered via lipid nanoparticles containing modified mRNA. ### Main Issues 1. **Low Engraftment Efficiency**: Currently, the engraftment efficiency of PHH transplantation is low, and the long-term effects are not satisfactory. 2. **Clinical Translation Barriers**: Existing preconditioning methods (such as partial hepatectomy, portal vein occlusion, etc.) can improve engraftment efficiency but are difficult to implement clinically and carry high risks. 3. **Insufficient Liver Regeneration Stimulation**: In patients with chronic liver disease, the proliferative capacity of hepatocytes is impaired, requiring effective regenerative stimulation to promote the proliferation of healthy cells. ### Solutions 1. **Using mRNA-LNP to Deliver Growth Factors**: The paper uses lipid nanoparticles (LNP) to deliver modified mRNA expressing human hepatocyte growth factor (HGF) and epidermal growth factor (EGF) to provide regenerative stimulation. 2. **Establishing More Accurate Animal Models**: By inducing hepatocyte p21 expression with AAV8-TBG-p21 virus, the study simulates the impaired hepatocyte proliferation seen in human chronic liver disease. 3. **Evaluating Therapeutic Effects**: The effects of HGF + EGF mRNA-LNP on PHH engraftment and liver function recovery are evaluated in two different mouse models (chronic liver disease model NSG-PiZ and acute liver injury model APAP overdose). ### Experimental Results 1. **Chronic Liver Disease Model (NSG-PiZ)**: - HGF + EGF mRNA-LNP significantly improved PHH engraftment efficiency, increasing PHH survival and proliferation. - Liver function in the treatment group was significantly improved, as evidenced by elevated serum albumin levels and reduced ALT liver function indicators. - Disease phenotype was alleviated, such as reduced Z-AAT polymer area. 2. **Acute Liver Injury Model (APAP Overdose)**: - HGF + EGF mRNA-LNP significantly improved PHH survival rate and increased the number of PHH engraftments. - Although PHH no longer proliferated after 2 weeks, the treatment group had more PHH clusters and higher serum albumin levels. ### Conclusion This study successfully improved PHH engraftment efficiency, reduced disease burden, and restored liver function in mouse models of chronic and acute liver disease by using mRNA-LNP to deliver HGF and EGF. This strategy may provide a new approach for clinical translation, potentially improving the efficacy of PHH transplantation in the treatment of liver diseases.

Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice

Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy to treat murine liver diseases

Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA

Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis

A cyclic peptide-grafted Fc with hepatocyte growth factor functionality ameliorates hepatic fibrosis in a non-alcoholic steatohepatitis mouse model

Therapeutic Cell Repopulation of the Liver: From Fetal Rat Cells to Synthetic Human Tissues

Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration

Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle

Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I.

Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis

Novel Efficient Lipid-Based Delivery Systems Enable a Delayed Uptake and Sustained Expression of mRNA in Human Cells and Mouse Tissues

Branched‐Tail Lipid Nanoparticles for Intravenous mRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice

Framework nucleic Acid-MicroRNA mediated hepatic differentiation and functional hepatic spheroid development for treating acute liver failure

Cryopreserved cGMP-compliant human pluripotent stem cell-derived hepatic progenitors rescue mice from acute liver failure through rapid paracrine effects on liver cells

Small Molecule Drugs Promote Repopulation of Transplanted Hepatocytes by Stimulating Cell Dedifferentiation

Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure.

Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes

Stable transduction of the neonatal mouse liver using a hybrid rAAV/sleeping beauty transposon gene delivery system

Delivery of Synthetic Interleukin-22 mRNA to Hepatocytes via Lipid Nanoparticles Alleviates Liver Injury

A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery

Physiologically-based modeling of LNP-mediated delivery of mRNA in the vascular system